|
Invited Speakers:
|
|
Confirmed speakers include: · Dr Jan M. Lundberg, Executive Vice President, Science & Technology & President, Lilly Research Labs, Eli Lilly and Companyo Dr Atul C. Pande, Senior Vice President, Neurosciences MDC, GlaxoSmithKlineo Joanne Waldstreicher, MD, CMO, Johnson & Johnson, Pharmaceuticalso Dr Menelas Pangalos, Executive Vice President & Global Head of Innovative Medicines, AstraZenecao Jeffrey M. Jonas MD, Senior Vice President, Specialty Pharma R&D, Shireo David Weiner MD, Senior Medical Director, Head of Early Clinical Development, Neurology Global Clinical Development Unit, EMD Serono, Inco Carmen Bozic MD, Senior Vice President & Global Head of Drug Safety & Risk Management, Biogen Ideco Ian C. Sanderson, Managing Director & Senior Pharmaceutical Research Analyst, Cowen and Companyo Dr Naomi Aronson, Executive Director, Technology Evaluation Center (TEC), BlueCross & BlueShield Associationo Dr Howard Feldman, Vice President & Therapeutic Area Head, Global Clinical Research, Neuroscience, Bristol-Myers Squibbo Dr Johan Luthman, Vice President, Neuroscience & Ophthalmology R&D, Franchise Integrator, Merck & Co, Inco Dr Michael Krams, Vice President - Head of Neurology Franchise, Johnson & Johnsono L. D. Altstiel, MD, PhD, Vice President, Head, Neuroscience Clinical Research, Pfizer Groton Research Laboratories, Pfizer Inco Dr William W. Chin, Executive Dean for Research, Harvard Medical Schoolo Michael Gold, MD, Vice President, Neurosciences Medicine Development Center, Medicine Development Leader, Alzheimer's Disease, GlaxoSmithKlineo Edwin H. Gordon, Managing Director, Ladenburg Thalmanno Dr Alan Cross, Chief Scientist, CNS Pain Research Area, AstraZenecao Dr Marc Berger, Vice President, Global Health Outcomes, Eli Lilly and Companyo Roy Baynes, MD, PhD, Vice President, Global Development & Therapeutic Area Head Hematology/Oncology, Amgen, Inco Dr Gillian Burgess, Vice President & Chief Scientific Officer, Pain Research, Pfizer Global R&Do Dr John V. W. Reynders, Head of Integrative Neurosciences & Biomarkers & Head of the Informatics Center of Excellence, Johnson & Johnsono Dr Eric Siemers, Medical Director, Alzheimer's Disease Team, Lilly Research Labs, Eli Lilly and Companyo Samer E. Kaba, MD, Medical Director, Neuroscience, Medpaceo Michael R. Fetell, MD, Vice President, Head of Neurology Search & Evaluation, Global Branded Products Business Development, Teva Branded Pharmaceutical Products R&D, Inco Sandra Panem, PhD, Partner, Cross Atlantic Partnerso Dr Donald R. Johns, Vice President, Deputy Global Head of Translational Medicine, Novartis Institutes for BioMedical Researcho Professor Jackie Hunter, CEO, Pharmivation Ltdo Erik B. Nielsen, Cand psych et Dr med, Director, Scientific Licensing, Corporate Business Development & Strategy, H. Lundbeck A/So Dr William (Bill) Matthew, Director of the Office of Translational Research, National Institute of Neurological Disorders & Strokeo Dr Sophie Banzet, Global Head, Safety Science, CNS, Safety Risk Management (PDS), F Hoffmann La Roche Ltdo Lon S. Schneider, MD, MS, Professor of Psychiatry, Neurology & Gerontology, University of Southern California Keck School of Medicine & Leonard Davis School of Gerontologyo Andrew R. Blight, PhD, Chief Scientific Officer, Acorda Therapeutics, Inco Samuel Agus, MD, Global Medical Affairs Director, Neurology, Global Product Strategy, Abbott Products Operations AGo Manuel O. Lopez-Figueroa, PhD, Vice President, Bay City Capital & Scientific Liaison, Pritzker Neuropsychiatric Disorders Research Consortiumo G.V. Campion MD PhD., Chief Medical Officer and Senior Vice President R&D, Prosensa Therapeutics BVo Dr Linda Brady, Director, Division of Neuroscience & Basic Behavioral Science, National Institute of Mental Health (NIMH)o Klaus Romero, MD, Clinical Pharmacologist, The Critical Path Institute o Karen Chen, PhD, Chief Scientific Officer, Spinal Muscular Atrophy Foundation
|
|